Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
19.99
+0.12 (0.60%)
At close: Mar 28, 2025, 4:00 PM
19.86
-0.13 (-0.65%)
After-hours: Mar 28, 2025, 4:54 PM EDT
Company Description
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
The company is developing DNTH103, a monoclonal antibody, which is in clinical-stage trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 78 |
| CEO | Marino Garcia |
Contact Details
Address: 7 Times Square, 43rd Floor New York, New York 10036 United States | |
| Phone | 929 999 4055 |
| Website | dianthustx.com |
Stock Details
| Ticker Symbol | DNTH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001690585 |
| CUSIP Number | 252828108 |
| ISIN Number | US2528281080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marino Garcia M.B.A. | President, Chief Executive Officer and Director |
| Ryan Savitz | Chief Financial Officer and Chief Business Officer |
| Simrat Randhawa M.B.A., M.D. | Chief Medical Officer |
| Edward G. Carr | Chief Accounting Officer |
| Judson Taylor | Senior Vice President and Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 24, 2025 | SCHEDULE 13G | Filing |
| Mar 19, 2025 | SCHEDULE 13D/A | Filing |
| Mar 11, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Dec 12, 2024 | 8-K | Current Report |